Trial Profile
A Study Investigating Plasma Abacavir and Its Intracellular Anabolite Carbovir-Triphosphate Pharmacokinetics in the Absence and in the Presence of Darunavir/Ritonavir or Raltegravir in HIV-Infected Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Abacavir (Primary) ; Darunavir; Nucleoside reverse transcriptase inhibitors; Raltegravir; Ritonavir
- Indications HIV-1 infections
- Focus Pharmacokinetics
- 01 Jan 2012 Results published in Antiviral Therapy.
- 20 Nov 2009 Actual patient number (29) added as reported by ClinicalTrials.gov.
- 20 Nov 2009 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.